ATE414280T1 - Dosierung von teichonsäuren von gram+-bakterien - Google Patents

Dosierung von teichonsäuren von gram+-bakterien

Info

Publication number
ATE414280T1
ATE414280T1 AT04767619T AT04767619T ATE414280T1 AT E414280 T1 ATE414280 T1 AT E414280T1 AT 04767619 T AT04767619 T AT 04767619T AT 04767619 T AT04767619 T AT 04767619T AT E414280 T1 ATE414280 T1 AT E414280T1
Authority
AT
Austria
Prior art keywords
gram
bacteria
teichoic acids
acids
dosing
Prior art date
Application number
AT04767619T
Other languages
English (en)
Inventor
Philippe Talaga
Patricia Sepulcri
Sandrine Vialle-Blanc
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE414280T1 publication Critical patent/ATE414280T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04767619T 2003-07-08 2004-07-08 Dosierung von teichonsäuren von gram+-bakterien ATE414280T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0308305A FR2857454B1 (fr) 2003-07-08 2003-07-08 Dosage des acides techoiques des bacteries gram+

Publications (1)

Publication Number Publication Date
ATE414280T1 true ATE414280T1 (de) 2008-11-15

Family

ID=33522837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04767619T ATE414280T1 (de) 2003-07-08 2004-07-08 Dosierung von teichonsäuren von gram+-bakterien

Country Status (6)

Country Link
EP (1) EP1646872B1 (de)
AT (1) ATE414280T1 (de)
CA (1) CA2531434C (de)
DE (1) DE602004017740D1 (de)
FR (1) FR2857454B1 (de)
WO (1) WO2005005988A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (de) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidin-derivate als jak1-inhibitoren
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
GB201011829D0 (en) 2010-07-14 2010-09-01 Two Trees Photonics Ltd Display system
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections

Also Published As

Publication number Publication date
EP1646872A2 (de) 2006-04-19
FR2857454A1 (fr) 2005-01-14
FR2857454B1 (fr) 2006-08-11
CA2531434A1 (en) 2005-01-20
WO2005005988A2 (fr) 2005-01-20
DE602004017740D1 (de) 2008-12-24
WO2005005988A3 (fr) 2005-04-07
CA2531434C (en) 2013-03-26
EP1646872B1 (de) 2008-11-12

Similar Documents

Publication Publication Date Title
ATE414280T1 (de) Dosierung von teichonsäuren von gram+-bakterien
Gening et al. Synthetic β-(1→ 6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens
BG102100A (bg) Методи за получаване на мономерни конюгати калихеамициново производно/носител
Berti et al. Role of O-acetylation in the immunogenicity of bacterial polysaccharide vaccines
Bales et al. Purification and characterization of biofilm-associated EPS exopolysaccharides from ESKAPE organisms and other pathogens
Sadovskaya et al. Extracellular carbohydrate-containing polymers of a model biofilm-producing strain, Staphylococcus epidermidis RP62A
BR112015029838A2 (pt) anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
ATE271060T1 (de) Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen
HRP20240847T1 (hr) Novi polisaharid i njegove upotrebe
Bertolo et al. Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile–ETEC conjugate vaccine
TW200642700A (en) Chemically defined stabiliser
Paton et al. Escherichia coli subtilase cytotoxin
Godefroid et al. Brucella melitensis 16M produces a mannan and other extracellular matrix components typical of a biofilm
DK1664123T3 (da) Storskalafremstilling af alfa-1-proteinaseinhibitor og anvendelse deraf
PL1654284T3 (pl) Sposób uzyskiwania roztworu alfa-1-antytrypsyny
Tullius et al. The lbgAB gene cluster of Haemophilus ducreyi encodes a β-1, 4-galactosyltransferase and an α-1, 6-dd-heptosyltransferase involved in lipooligosaccharide biosynthesis
Ghequire et al. Draft genome sequence of Pseudomonas putida BW11M1, a banana rhizosphere isolate with a diversified antimicrobial armamentarium
WO2018083490A3 (en) Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms
IT1265964B1 (it) Micro-granuli ottenuti tramite estrusione-sferonizzazione contenenti una ciclodestrina.
CN104667272A (zh) 一种动物免疫佐剂及其制备方法和使用方法
JPS56147801A (en) Alpha-glycosylpullulan
RU2008104770A (ru) Полисахарид, вырабатываемый микроорганизмом, принадлежащим к роду bifidobacterium
Eyngor et al. A pivotal role for the Streptococcus iniae extracellular polysaccharide in triggering proinflammatory cytokines transcription and inducing death in rainbow trout
CN202220169U (zh) 一种方便取样的细菌培养瓶
Jing et al. Optimization of Fermentation Process for Hyaluronic Acid Production by Streptococcus zooepidemicus.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1646872

Country of ref document: EP